◼ Archived
Business
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
3 trends tracked about this subject — the full history, oldest to newest below.
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
12 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A genetic link to IBD has been pinpointed after decades of uncertainty—here’s what’s driving the breakthrough